<p>Praxis Precision Medicines, Inc.（纳斯达克代码：PRAX - 获取免费报告）在周一的交易中达到了新的 52 周高点。该公司交易价格最高达到 303.00 美元，最后交易价格为 315.0280 美元，成交量为 26671 股。该股票之前的收盘价为 268.95 美元。</p>
<h2>分析师设定新的价格目标</h2>
<p>多家股票研究分析师最近对 PRAX 股票发表了看法。Oppenheimer 在 12 月 15 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Praxis Precision Medicines 的目标价设定为 750.00 美元（上调自 250.00 美元）。德意志银行在 12 月 12 日的研究报告中将 Praxis Precision Medicines 的目标价设定为 313.00 美元。Wedbush 在 12 月 5 日的研究报告中重新发布了 “跑输大盘” 的评级，并将 Praxis Precision Medicines 的目标价设定为 83.00 美元（上调自 77.00 美元）。Needham &amp; Company LLC 在 12 月 8 日的研究报告中将 Praxis Precision Medicines 的目标价从 304.00 美元上调至 315.00 美元，并给予该公司 “买入” 评级。最后，HC Wainwright 在 12 月 5 日的研究报告中重申了 “买入” 评级，并将 Praxis Precision Medicines 的目标价设定为 340.00 美元（上调自 258.00 美元）。两位研究分析师对该股票给予了强烈买入评级，十三位给予了买入评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，Praxis Precision Medicines 的共识评级为 “适度买入”，平均目标价为 426.20 美元。</p>
<p><strong>查看我们关于 Praxis Precision Medicines 的最新股票报告</strong></p>
<h2>Praxis Precision Medicines 股价上涨 15.8%</h2>
<p>该公司的 50 日简单移动平均线为 210.93 美元，200 日简单移动平均线为 107.38 美元。该公司的市值为 77.9 亿美元，市盈率为-23.87，贝塔值为 2.95。</p>
<p>Praxis Precision Medicines（纳斯达克代码：PRAX - 获取免费报告）最近在 11 月 5 日发布了其财报。该公司报告每股收益（EPS）为-3.36 美元，超出分析师的共识预期（-3.45 美元）0.09 美元。卖方分析师预测 Praxis Precision Medicines, Inc.在当前财政年度将发布-10.22 的每股收益。</p>
<h2>内部交易活动</h2>
<p>在相关消息中，内部人士 Lauren Mastrocola 在 11 月 20 日的交易中出售了 13600 股该公司的股票。这些股票以平均 192.08 美元的价格出售，总价值为 2612288.00 美元。出售完成后，该内部人士持有 10442 股公司股票，价值约为 2005699.36 美元。此次交易使其持股减少了 56.57%。该出售在与证券交易委员会的法律文件中披露，可以通过此链接访问。此外，首席法律顾问 Alex Nemiroff 在 11 月 20 日的交易中出售了 25130 股 Praxis Precision Medicines 的股票。这些股票以平均 193.09 美元的价格出售，总交易额为 4852351.70 美元。出售完成后，首席法律顾问持有 20832 股公司股票，价值约为 4022450.88 美元。此次交易使其持股减少了 54.68%。有关此次出售的更多细节可在官方 SEC 披露中找到。公司内部人士持有公司股票的 2.70%。</p>
<h2>机构投资者对 Praxis Precision Medicines 的看法</h2>
<p>机构投资者最近对该股票的持仓进行了调整。Nuveen LLC 在第一季度购买了 Praxis Precision Medicines 的新头寸，价值约为 559,000 美元。Adage Capital Partners GP L.L.C.在第一季度将其在 Praxis Precision Medicines 的股份增加了 188.1%。Adage Capital Partners GP L.L.C.现在拥有 1742758 股公司股票，价值 65998000 美元，此前在该期间内又购买了 1137748 股。Ally Bridge Group NY LLC 在第一季度将其在 Praxis Precision Medicines 的持股增加了 112.5%。Ally Bridge Group NY LLC 现在拥有 95582 股公司股票，价值 3620000 美元，此前在上个季度又购买了 50600 股。Cormorant Asset Management LP 在第一季度将其在 Praxis Precision Medicines 的股份增加了 3.1%。Cormorant Asset Management LP 现在拥有 1745000 股公司股票，价值 66083000 美元，此前在上个季度又购买了 51781 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Praxis Precision Medicines 的持股增加了 5.1%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 11708 股公司股票，价值 444000 美元，此前在该期间内又购买了 573 股。目前 67.84% 的股票由机构投资者和对冲基金持有。</p>
<h2>Praxis Precision Medicines 公司简介</h2>
<p>（获取免费报告）</p>
<p>Praxis Precision Medicines 是一家临床阶段的生物制药公司，专注于发现和开发针对神经兴奋性驱动的疾病的精准疗法。该公司应用转化神经科学和基因洞察，设计针对特定离子通道和受体亚型的小分子药物，这些通道和亚型与神经和精神疾病相关。其研究旨在解决在罕见癫痫、特发性震颤、耐药性抑郁症及其他中枢神经系统（CNS）疾病中的未满足需求。</p>
<p>该公司的产品管线包括多个处于不同开发阶段的主要候选药物。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过 Praxis Precision Medicines</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股” 即将爆发</li>
<li>100 万美元在退休中能维持多久？</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Praxis Precision Medicines 吗？</h2>
<p>在考虑 Praxis Precision Medicines 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Praxis Precision Medicines 并不在名单上。</p>
<p>虽然 Praxis Precision Medicines 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

PRAX

<p>Praxis Precision Medicines（纳斯达克代码：PRAX）达到了新的 52 周高点 315.03 美元，较之前的收盘价 268.95 美元上涨。分析师们设定了不同的目标价，其中 Oppenheimer 将其目标价提高至 750.00 美元。该股票的共识评级为 “适度买入”，平均目标价为 426.20 美元。公司报告的每股收益为（3.36 美元），超出预期。内部交易活动包括高管的重大出售。机构投资者持有 67.84% 的股份，显示出强烈的机构兴趣</p>

<p>Praxis Precision Medicines, Inc. (NASDAQ:PRAX - Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $303.00 and last traded at $315.0280, with a volume of 26671 shares changing hands. The stock had previously closed at $268.95.</p>
<div class="lb-trans"><p>Praxis Precision Medicines, Inc.（纳斯达克代码：PRAX - 获取免费报告）在周一的交易中达到了新的 52 周高点。该公司交易价格最高达到 303.00 美元，最后交易价格为 315.0280 美元，成交量为 26671 股。该股票之前的收盘价为 268.95 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of equities research analysts recently weighed in on PRAX shares. Oppenheimer restated an &#34;outperform&#34; rating and set a $750.00 price objective (up from $250.00) on shares of Praxis Precision Medicines in a research note on Monday, December 15th. Deutsche Bank Aktiengesellschaft set a $313.00 price objective on shares of Praxis Precision Medicines in a research report on Friday, December 12th. Wedbush reissued an &#34;underperform&#34; rating and set a $83.00 target price (up previously from $77.00) on shares of Praxis Precision Medicines in a research report on Friday, December 5th. Needham &amp; Company LLC raised their target price on shares of Praxis Precision Medicines from $304.00 to $315.00 and gave the company a &#34;buy&#34; rating in a research note on Monday, December 8th. Finally, HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $340.00 price target (up from $258.00) on shares of Praxis Precision Medicines in a research report on Friday, December 5th. Two research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Praxis Precision Medicines has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $426.20.</p>
<div class="lb-trans"><p>多家股票研究分析师最近对 PRAX 股票发表了看法。Oppenheimer 在 12 月 15 日的研究报告中重申了 “跑赢大盘” 的评级，并将 Praxis Precision Medicines 的目标价设定为 750.00 美元（上调自 250.00 美元）。德意志银行在 12 月 12 日的研究报告中将 Praxis Precision Medicines 的目标价设定为 313.00 美元。Wedbush 在 12 月 5 日的研究报告中重新发布了 “跑输大盘” 的评级，并将 Praxis Precision Medicines 的目标价设定为 83.00 美元（上调自 77.00 美元）。Needham &amp; Company LLC 在 12 月 8 日的研究报告中将 Praxis Precision Medicines 的目标价从 304.00 美元上调至 315.00 美元，并给予该公司 “买入” 评级。最后，HC Wainwright 在 12 月 5 日的研究报告中重申了 “买入” 评级，并将 Praxis Precision Medicines 的目标价设定为 340.00 美元（上调自 258.00 美元）。两位研究分析师对该股票给予了强烈买入评级，十三位给予了买入评级，两位给予了卖出评级。根据 MarketBeat.com 的数据，Praxis Precision Medicines 的共识评级为 “适度买入”，平均目标价为 426.20 美元。</p>
</div><p><strong>Check Out Our Latest Stock Report on Praxis Precision Medicines</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Praxis Precision Medicines 的最新股票报告</strong></p>
</div><h2>Praxis Precision Medicines Trading Up 15.8%</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 股价上涨 15.8%</h2>
</div><p>The business's 50-day simple moving average is $210.93 and its 200-day simple moving average is $107.38. The company has a market capitalization of $7.79 billion, a PE ratio of -23.87 and a beta of 2.95.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 210.93 美元，200 日简单移动平均线为 107.38 美元。该公司的市值为 77.9 亿美元，市盈率为-23.87，贝塔值为 2.95。</p>
</div><p>Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.45) by $0.09. Sell-side analysts forecast that Praxis Precision Medicines, Inc. will post -10.22 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Praxis Precision Medicines（纳斯达克代码：PRAX - 获取免费报告）最近在 11 月 5 日发布了其财报。该公司报告每股收益（EPS）为-3.36 美元，超出分析师的共识预期（-3.45 美元）0.09 美元。卖方分析师预测 Praxis Precision Medicines, Inc.在当前财政年度将发布-10.22 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部交易活动</h2>
</div><p>In related news, insider Lauren Mastrocola sold 13,600 shares of the business's stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $192.08, for a total value of $2,612,288.00. Following the completion of the sale, the insider owned 10,442 shares of the company's stock, valued at approximately $2,005,699.36. The trade was a 56.57% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, General Counsel Alex Nemiroff sold 25,130 shares of Praxis Precision Medicines stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $193.09, for a total transaction of $4,852,351.70. Following the completion of the sale, the general counsel owned 20,832 shares in the company, valued at approximately $4,022,450.88. This trade represents a 54.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 2.70% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Lauren Mastrocola 在 11 月 20 日的交易中出售了 13600 股该公司的股票。这些股票以平均 192.08 美元的价格出售，总价值为 2612288.00 美元。出售完成后，该内部人士持有 10442 股公司股票，价值约为 2005699.36 美元。此次交易使其持股减少了 56.57%。该出售在与证券交易委员会的法律文件中披露，可以通过此链接访问。此外，首席法律顾问 Alex Nemiroff 在 11 月 20 日的交易中出售了 25130 股 Praxis Precision Medicines 的股票。这些股票以平均 193.09 美元的价格出售，总交易额为 4852351.70 美元。出售完成后，首席法律顾问持有 20832 股公司股票，价值约为 4022450.88 美元。此次交易使其持股减少了 54.68%。有关此次出售的更多细节可在官方 SEC 披露中找到。公司内部人士持有公司股票的 2.70%。</p>
</div><h2>Institutional Investors Weigh In On Praxis Precision Medicines</h2>
<div class="lb-trans"><h2>机构投资者对 Praxis Precision Medicines 的看法</h2>
</div><p>Institutional investors have recently made changes to their positions in the stock. Nuveen LLC purchased a new position in Praxis Precision Medicines in the 1st quarter valued at approximately $559,000. Adage Capital Partners GP L.L.C. increased its stake in shares of Praxis Precision Medicines by 188.1% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,742,758 shares of the company's stock worth $65,998,000 after acquiring an additional 1,137,748 shares during the period. Ally Bridge Group NY LLC boosted its holdings in Praxis Precision Medicines by 112.5% in the 1st quarter. Ally Bridge Group NY LLC now owns 95,582 shares of the company's stock valued at $3,620,000 after purchasing an additional 50,600 shares in the last quarter. Cormorant Asset Management LP raised its stake in shares of Praxis Precision Medicines by 3.1% during the 1st quarter. Cormorant Asset Management LP now owns 1,745,000 shares of the company's stock worth $66,083,000 after buying an additional 51,781 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Praxis Precision Medicines by 5.1% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,708 shares of the company's stock worth $444,000 after acquiring an additional 573 shares during the period. 67.84% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者最近对该股票的持仓进行了调整。Nuveen LLC 在第一季度购买了 Praxis Precision Medicines 的新头寸，价值约为 559,000 美元。Adage Capital Partners GP L.L.C.在第一季度将其在 Praxis Precision Medicines 的股份增加了 188.1%。Adage Capital Partners GP L.L.C.现在拥有 1742758 股公司股票，价值 65998000 美元，此前在该期间内又购买了 1137748 股。Ally Bridge Group NY LLC 在第一季度将其在 Praxis Precision Medicines 的持股增加了 112.5%。Ally Bridge Group NY LLC 现在拥有 95582 股公司股票，价值 3620000 美元，此前在上个季度又购买了 50600 股。Cormorant Asset Management LP 在第一季度将其在 Praxis Precision Medicines 的股份增加了 3.1%。Cormorant Asset Management LP 现在拥有 1745000 股公司股票，价值 66083000 美元，此前在上个季度又购买了 51781 股。最后，MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.在第一季度将其在 Praxis Precision Medicines 的持股增加了 5.1%。MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.现在拥有 11708 股公司股票，价值 444000 美元，此前在该期间内又购买了 573 股。目前 67.84% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Praxis Precision Medicines Company Profile</h2>
<div class="lb-trans"><h2>Praxis Precision Medicines 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.</p>
<div class="lb-trans"><p>Praxis Precision Medicines 是一家临床阶段的生物制药公司，专注于发现和开发针对神经兴奋性驱动的疾病的精准疗法。该公司应用转化神经科学和基因洞察，设计针对特定离子通道和受体亚型的小分子药物，这些通道和亚型与神经和精神疾病相关。其研究旨在解决在罕见癫痫、特发性震颤、耐药性抑郁症及其他中枢神经系统（CNS）疾病中的未满足需求。</p>
</div><p>The company's pipeline includes several lead candidates at various stages of development.</p>
<div class="lb-trans"><p>该公司的产品管线包括多个处于不同开发阶段的主要候选药物。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Praxis Precision Medicines</li>
<li>Do not delete, read immediately</li>
<li>How the Rich Retire</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>How Long Will $1M Last in Retirement?</li>
<li>[No Brainer Gold Play]: “Show me a better investment.”</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Praxis Precision Medicines</li>
<li>请勿删除，立即阅读</li>
<li>富人如何退休</li>
<li>投资者警报：微型 “3 美元人工智能奇迹股” 即将爆发</li>
<li>100 万美元在退休中能维持多久？</li>
<li>[无脑黄金投资]：“给我一个更好的投资。”</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Praxis Precision Medicines Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Praxis Precision Medicines 吗？</h2>
</div><p>Before you consider Praxis Precision Medicines, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Praxis Precision Medicines 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Praxis Precision Medicines 并不在名单上。</p>
</div><p>While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Praxis Precision Medicines 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Praxis Precision Medicines（NASDAQ 代码：PRAX）创下新的 12 个月高点 - 现在是买入的好时机吗？